Thermo Fisher Collaborates with JW Therapeutics for CAR-T Therapies in China
Shots:
- The companies signed an agreement to ensure non-exclusive commercial access to Thermo Fisher’s Gibco CTS Dynabeads CD3/CD28
- The focus of the agreement is to support clinical development & commercial manufacturing of leading CAR-T therapies in China including JW’s relmacabtagene autoleucel (relma-cel)
- Relma-cel is an anti-CD19 CAR-T therapy for 3L treatment for r/r B-cell lymphoma and is expected to be first CAR-T therapy to be approved as a Category 1 biologics in China. Additionally- NMPA has accepted the NDA of Relma-cel
Ref: PRNewswire | Image: The Spruce
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com